Promising sarcoma combo study pulled before enrolling a single patient
NCT ID NCT06116578
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 20 times
Summary
This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS). Participants would have received either pembrolizumab alone or combined with olaparib before surgery, followed by more pembrolizumab after. The goal was to see if these drugs boost immune activity in the tumor. However, the study was withdrawn before any patients enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94800, France
Conditions
Explore the condition pages connected to this study.